Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-9131 Functional Monotherapy in HIV-1
NCT03472326Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Apr 2018
- Primary completion
- Dec 2019
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 2 trial of rovafovir etalafenamide in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Apr 2018; status: terminated.
02
Drugs
rovafovir etalafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03472326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472326.